Commentary on the Chinese guideline for diagnosis and treatment of myasthenia gravis (2025 edition)
10.3760/cma.j.cn113694-20250418-00221
- VernacularTitle:中国重症肌无力诊断和治疗指南（2025版）评述
- Author:
Wenjia ZHU
1
;
Yuwei DA
1
Author Information
1. 首都医科大学宣武医院神经内科，北京 100053
- Publication Type:Journal Article
- Keywords:
Myasthenia gravis;
Diagnosis;
Treatment;
Guideline;
Editorial
- From:
Chinese Journal of Neurology
2025;58(7):672-679
- CountryChina
- Language:Chinese
-
Abstract:
The Chinese guideline for the diagnosis and treatment of myasthenia gravis (2025 edition), rooted in evidence-based medicine and the latest global research advancements, comprehensively optimized the diagnostic and therapeutic strategies for myasthenia gravis (MG). The guideline prioritized the cell-based immunofluorescence assay for detecting pathogenic antibodies. These updates were integrated with clinical features to enhance differential diagnostic approaches. The guideline proposed incorporating disease activity stratification into the MG evaluation system. By tailoring strategies to disease activity levels, clinical status, and characteristics of different patient subgroups, the guideline emphasized precision in formulating personalized treatment plans. It also provided explicit methodologies for goal-oriented therapy and maintenance therapy. The guideline refined the management of special populations, establishing differentiated protocols for juvenile, pregnant, very-late-onset, and refractory MG patients, balancing efficacy and safety. The guideline introduced the safety and individualized assessments for MG vaccination. The updated guideline highlighted multidisciplinary comprehensive management and long-term efficacy tracking of biologics, promoting precision management of MG across the entire patient lifecycle.
